CED

Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference

Retrieved on: 
Montag, Mai 20, 2024
Patient, DDW, Inflammation, Doctor of Philosophy, BOCA, Lymphocyte, Clinical trial, Diagnosis, Coeliac disease, Therapy, Health, Conference, Database, Serology, Research, IEL, Poster, Diet, CED, Management

BOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, yesterday presented two posters on celiac disease research at the 2024 Digestive Disease Week (DDW 2024) Conference in Washington, D.C.

Key Points: 
  • BOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, yesterday presented two posters on celiac disease research at the 2024 Digestive Disease Week (DDW 2024) Conference in Washington, D.C.
  • The presentations draw upon research from the robust clinical program investigating latiglutenase, an oral biotherapeutic being developed as a potentially first-in-class, targeted, oral biotherapeutic for celiac disease (CeD).
  • “These findings will enable us to better monitor celiac disease and refine the tools we use in its diagnosis,” said Jack Syage, Ph.D., President and Chief Scientific Officer of Entero Therapeutics.
  • President & Chief Scientific Officer, Entero Therapeutics; Jennifer Sealy-Voyksner, PhD., Vice President R&D, Entero Therapeutics

Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
Mittwoch, Mai 15, 2024
Cancer, Neuro, Molecular imaging, Feasibility, Patient, Ependymoma, Plus Therapeutics, Treatment, SNMMI, FDA, IND, CED, Anticipation, Therapy, Trial of the century, Conference, Breast cancer, Society, Nuclear medicine, Acquisition, PSTV, Spinal cord, LM, Completeness, Safety, Meninges, Webcast, Biomarker, Annual general meeting, Pharmaceutical industry

AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent and upcoming business highlights.

Key Points: 
  • ET
    AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent and upcoming business highlights.
  • Additional detail on the acquisition can be found here
    Strengthened management team with appointments of neuro-oncologist Andrew Brenner, M.D.
  • Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call.
  • The webcast will be available on the Company’s website for 90 days following the live call.

Anokion Announces New Clinical Data from the Phase 1b/2 ACeD-it Trial Supporting KAN-101 as a Potential Disease-Modifying Treatment for Celiac Disease

Retrieved on: 
Montag, Mai 20, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Immune tolerance, Patient, DDW, Coeliac disease, Autoimmune disease, CED, Pharmaceutical industry

Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced additional favorable safety and efficacy data from the company’s ongoing Phase 1b/2 clinical trial (ACeD-it) evaluating KAN-101 as a treatment for celiac disease.

Key Points: 
  • Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced additional favorable safety and efficacy data from the company’s ongoing Phase 1b/2 clinical trial (ACeD-it) evaluating KAN-101 as a treatment for celiac disease.
  • Anokion’s Phase 1b/2 ACeD-it (assessment of KAN-101 in Celiac Disease) trial is expecting to enroll up to 120 patients.
  • The Phase 1b portion is an open-label trial with multi-ascending dose (MAD) cohorts and the Phase 2 portion is a double-blind, placebo-controlled, parallel design trial.
  • The Company is actively enrolling patients into its Phase 2 portion of the Phase 1/b ACeD-it trial and its Phase 2a SynCeD trial in individuals with Celiac Disease.

CED Issues Statement on 2024 Social Security and Medicare Trustees Reports

Retrieved on: 
Mittwoch, Mai 8, 2024
Congress, Public policy, Social Security, Social, Private law, The Conference Board, Conference, Trustee, Debt crisis, Medicare, Committee, CED, Economic development, Cryptocurrency

NEW YORK, May 8, 2024 /PRNewswire/ -- Today, John Gardner, Vice President, Public Policy at the Committee for Economic Development (CED), the public policy center of The Conference Board, released the following statement:

Key Points: 
  • NEW YORK, May 8, 2024 /PRNewswire/ -- Today, John Gardner, Vice President, Public Policy at the Committee for Economic Development (CED), the public policy center of The Conference Board, released the following statement:
    The 2024 Social Security and Medicare Trustees reports demand action: The Debt Crisis is here, and Congress must urgently act to address the solvency of the Trust Funds.
  • While stronger-than-expected economic growth in 2023 slightly improved the financial projections for these programs, long-term demographic changes pose structural challenges for vital retirement and healthcare benefits for seniors and the disabled.
  • We reiterate our call for a bipartisan Congressional Commission on Fiscal Responsibility to consider comprehensive and sustainable solutions and urge Congress to adopt solutions both to avoid the short-term insolvency of the Social Security OASI Trust Fund and put the Social Security and Medicare Trust Funds on sound financial footing to preserve these crucial programs for current beneficiaries and future generations of Americans.

First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients

Retrieved on: 
Mittwoch, April 24, 2024
First wave, CED, Research, Coeliac disease, ULN, Serology, Patient, Diet, BOCA, Manuscript, Pharmaceutical industry

Latiglutenase, an oral biotherapeutic composed of two gluten-specific recombinant proteases, is a potentially first-in-class, targeted, oral biotherapeutic for celiac disease (CeD).

Key Points: 
  • Latiglutenase, an oral biotherapeutic composed of two gluten-specific recombinant proteases, is a potentially first-in-class, targeted, oral biotherapeutic for celiac disease (CeD).
  • The featured paper is entitled “Dynamics of Serologic Change to Gluten in Celiac Disease Patients” (doi.org/10.3390/nu15245083).
  • “Our focus on developing latiglutenase is bolstered by this groundbreaking CeD research, just one component of the scientific, clinical, and regulatory expertise in gastroenterological drug development that Jack Syage and his team, formerly from ImmunogenX, bring to First Wave,” stated James Sapirstein, Chairman and CEO of First Wave.
  • “The evidence produced from this rich deposit of clinical data advances not only the development of latiglutenase but also benefits the whole field of celiac disease research in order to bring needed relief to the millions who suffer from this disease.”

CED Announces Recipients of Its 2024 Distinguished Leadership Awards

Retrieved on: 
Donnerstag, April 18, 2024
Corporation, The Conference Board, Conference, Public policy, Byron Boston, Committee, CED, Economic development

NEW YORK, April 18, 2024 /PRNewswire/ -- Today, the Committee for Economic Development, the public policy center of The Conference Board (CED), announced the outstanding business leaders and their companies that will be receiving the 2024 CED Distinguished Leadership Awards.

Key Points: 
  • NEW YORK, April 18, 2024 /PRNewswire/ -- Today, the Committee for Economic Development, the public policy center of The Conference Board (CED), announced the outstanding business leaders and their companies that will be receiving the 2024 CED Distinguished Leadership Awards.
  • The 2024 Awards Celebration will be held on October 9, 2024, in New York City, where the honorees will be introduced by leading executives—all of whom are distinguished leaders in their own right.
  • This year's CED Awards Committee is co-chaired by Peter Altabef, Chair and CEO of Unisys; Byron Boston, Chairman and CEO of Dynex Capital, Inc.; and Dr. Lori Esposito Murray, CED Trustee and former President of CED.
  • CED is pleased to announce the recipients of the 2024 Distinguished Leadership Awards for Business Stewardship and Corporate Citizenship:

aiOla's Speech AI Technology Outperforms OpenAI's Whisper in Recognizing Jargon

Retrieved on: 
Donnerstag, April 18, 2024
Speech, OpenAI, Automation, CED, Whispering, Communication, TEL, Safety

TEL AVIV, Israel, April 18, 2024 /PRNewswire/ -- aiOla, an AI-powered technology that automates business workflows by capturing spoken data, has announced a major milestone in speech recognition. aiOla's solution, powered by a novel keyword spotting model, has advanced to match human proficiency in understanding industry-specific jargon. The patented AdaKWS model achieved 95% accuracy in keyword spotting, surpassing OpenAI's industry-leading Whisper model which reached 88% accuracy.

Key Points: 
  • aiOla's solution, powered by a novel keyword spotting model, has advanced to match human proficiency in understanding industry-specific jargon.
  • Keyword spotting is an essential aspect of speech recognition that tackles the problem of identifying jargon by detecting predefined words and phrases.
  • aiOla's process automation applications can accurately understand speech, jargon and acronyms across over 100 languages, regardless of accents and background noises.
  • This enables aiOla's solution to be instantly adapted to the jargon of any industry without needing to retrain its AI model.

aiOla's Speech AI Technology Outperforms OpenAI's Whisper in Recognizing Jargon

Retrieved on: 
Donnerstag, April 18, 2024
Speech, OpenAI, Automation, CED, Whispering, Communication, TEL, Safety

TEL AVIV, Israel, April 18, 2024 /PRNewswire/ -- aiOla, an AI-powered technology that automates business workflows by capturing spoken data, has announced a major milestone in speech recognition. aiOla's solution, powered by a novel keyword spotting model, has advanced to match human proficiency in understanding industry-specific jargon. The patented AdaKWS model achieved 95% accuracy in keyword spotting, surpassing OpenAI's industry-leading Whisper model which reached 88% accuracy.

Key Points: 
  • aiOla's solution, powered by a novel keyword spotting model, has advanced to match human proficiency in understanding industry-specific jargon.
  • Keyword spotting is an essential aspect of speech recognition that tackles the problem of identifying jargon by detecting predefined words and phrases.
  • aiOla's process automation applications can accurately understand speech, jargon and acronyms across over 100 languages, regardless of accents and background noises.
  • This enables aiOla's solution to be instantly adapted to the jargon of any industry without needing to retrain its AI model.

As AI Transforms the Economy, CED Provides Plan to Future-Proof Workforce

Retrieved on: 
Dienstag, April 16, 2024
Education, Public policy, Workforce, System, Learning, NIH, Policy, AI, The Conference Board, Conference, Federal, Research, STEM, NSF, Committee, Private sector, CED, Student, Capitalism, Economic development, Knowledge, Management

It offers solutions for business and policy leaders to respond proactively to the AI transformation by equipping workers with the knowledge and tools to adapt and thrive.

Key Points: 
  • It offers solutions for business and policy leaders to respond proactively to the AI transformation by equipping workers with the knowledge and tools to adapt and thrive.
  • "AI's impact on workers and the economy is simply too large—and consequential—to be ignored," said John Gardner, Vice President, Public Policy at CED.
  • Expand Federal AI research initiatives in academic institutions through NSF, NIH, and other agencies, including research on human-complementary technology.
  • Build AI expertise to drive government's response to AI challenges and to review and advise on how government workers use AI technology.

CED Testifies Before Congress on Child Care's Economic Impact

Retrieved on: 
Donnerstag, April 11, 2024
Congress, Small business, Hearing, Child care, The Conference Board, Conference, Parent, Research, Public policy, Environment, Committee, Workforce, CED, Student, Role, Economic development, Entrepreneurship, Management

NEW YORK, April 11, 2024 /PRNewswire/ -- The Committee for Economic Development (CED), the public policy center of The Conference Board, testified before Congress earlier this week.

Key Points: 
  • NEW YORK, April 11, 2024 /PRNewswire/ -- The Committee for Economic Development (CED), the public policy center of The Conference Board, testified before Congress earlier this week.
  • The testimony was given by Cindy Cisneros, Vice President of Education Programs at CED, who spoke about CED's findings and recommendations from its report, Child Care in State Economies , addressing issues related to the accessibility and affordability of quality child care.
  • The economic model for child care makes it difficult for home-based providers to stay in the business and for child care centers to hire and retain high-quality staff, which also impacts choices for parents.
  • While there is no easy way to make quality child care more available and affordable, there are a variety of approaches to address child care supply and cost.